Prescribing information and adverse event reporting information for EYLEA® (aflibercept) can be accessed here or via the QR code located on the last page of this document.

EYLEA® 8mg
(aflibercept 114.3mg/mL, solution for injection)



EYLEA 8 mg DOSING REGIMENS IN nAMD, DMO AND RVO

Treat your eligible patients with flexibility with **Q4 to Q24** dosing for **nAMD/DMO** and **Q4 to Q20** dosing in **RVO**[1]

EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular oedema (DMO) and visual impairment due to macular oedema secondary to retinal vein occlusion (branch, central and hemiretinal RVO).[1]

For UK healthcare professionals only. This promotional material was organised and fully funded by Bayer plc.

DMO, diabetic macular oedema. nAMD, neovascular age-related macular degeneration. Q4, every 4 weeks. Q20, every 20 weeks. Q24, every 24 weeks. RVO, retinal vein occlusion.

References

1. EYLEA® 114.3 mg/mL Summary of Product Characteristics.

PP-EYL_8mg-GB-0951 | March 2026

TREAT YOUR ELIGIBLE PATIENTS WITH FLEXIBILITY

Tx-naïve | Switch

For patients initiating treatment, EYLEA 8 mg can be used as part of a treat-and-extend regimen[1]



Frequency of monitoring visits should be based on patient status and at physician's discretion.[1] Consult the SmPC for full safety profile.

EYLEA 8 mg offers a flexible posology with Q4 to Q24 dosing for nAMD/DMO and Q4 to Q20 dosing in RVO[1]

Dosing diagram for illustrative purposes only.

*If visual and/or anatomic outcomes deteriorate, the treatment interval should be shortened accordingly based on the physician's discretion. nAMD and DMO injection intervals may be extended up to every 4 months based on physician's judgement of visual and/or anatomic outcomes. Subsequently, treatment intervals may be further extended up to 6 months, such as with a treat-and-extend (T&E) dosing regimen, while maintaining stable visual and/or anatomic outcomes. RVO Injection intervals may be extended based on the physician's judgement of visual and/or anatomic outcomes. The shortest interval between 2 injections is 1 month. For full details of posology and situations in which treatment should be withheld see the EYLEA® 114.3 mg/mL Summary of Product Characteristics.[1]

DMO, diabetic macular oedema. nAMD, neovascular age-related macular degeneration. Q4, every 4 weeks. Q20, every 20 weeks. Q24, every 24 weeks. RVO, retinal vein occlusion. SmPC, Summary of Product Characteristics. Tx, treatment.

Reference: 1. EYLEA® 114.3 mg/mL Summary of Product Characteristics.

TREAT YOUR ELIGIBLE PATIENTS WITH FLEXIBILITY

Tx-naïve | Switch

Patients previously treated with anti-VEGF treatments can maintain or extend their current interval when switching to EYLEA 8 mg, with or without reloading*[1]



Frequency of monitoring visits should be based on patient status and at physician's discretion.[1] Consult the SmPC for full safety profile.

EYLEA 8 mg offers a flexible posology with Q4 to Q24 dosing for nAMD/DMO and Q4 to Q20 dosing in RVO[1]

Dosing diagram for illustrative purposes only.

*If visual and/or anatomic outcomes deteriorate, the treatment interval should be shortened accordingly based on the physician's discretion. nAMD and DMO injection intervals may be extended up to every 4 months based on physician's judgement of visual and/or anatomic outcomes. Subsequently, treatment intervals may be further extended up to 6 months, such as with a treat-and-extend (T&E) dosing regimen, while maintaining stable visual and/or anatomic outcomes. RVO Injection intervals may be extended based on the physician's judgement of visual and/or anatomic outcomes. The shortest interval between 2 injections is 1 month. For full details of posology and situations in which treatment should be withheld see the EYLEA® 114.3 mg/mL Summary of Product Characteristics.[1]

DMO, diabetic macular oedema. nAMD, neovascular age-related macular degeneration. Q4, every 4 weeks. Q20, every 20 weeks. Q24, every 24 weeks. RVO, retinal vein occlusion. SmPC, Summary of Product Characteristics. Tx, treatment. VEGF, vascular endothelial growth factor.

Reference: 1. EYLEA® 114.3 mg/mL Summary of Product Characteristics.

Prescribing information and adverse event reporting information for EYLEA® (aflibercept) is available via the QR code on the right.

Either click **here** or scan the QR code for prescribing information and adverse event reporting information.

For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.